Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Denmark: Metosyn; Germany: Topsym; Greece: Lidex; Italy: Topsyn.

North America

Canada: Lidemol, Lidex, Lyderm, Tiamol, Topactin; USA: Fluocinonide, Lidex, Vanos.

Latin America

Mexico: Topsyn.


Japan: Lidex, Vanos.

Drug combinations

Fluocinonide and Clioquinol

Fluocinonide and Lidocaine

Drug combinations


Fluocinonide: C~26~H~32~F~2~O~7~. Mw: 494.52. (1) 6α,9-difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone,21-acetate. (2) Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6a,11b,16a)-. CAS-356-12-7.

Pharmacologic Category

Antipruritics and Local Anesthetics. Antipsoriatic Agents. Topical Corticosteroid. (ATC-Code: C05AA11; D07AC08).

Mechanism of action

Fluorinated topical corticosteroid considered to be of high potency. The mechanism of action for all topical corticosteroids is not well defined; however, it is considered to be a combination of three important properties: anti-inflammatory activity, immunosuppressive properties, and antiproliferative actions.

Therapeutic use

Anti-inflammatory, antipruritic; treatment of plaque-type psoriasis (up to 10% of body surface area) [high-potency topical corticosteroid].

Pregnancy and lactiation implications

Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. Systemically administered corticosteroids are secreted into breast milk in quantities that are not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Unlabeled use

Dental use: Relief of inflammatory and pruritic manifestations (high potency topical corticosteroid).


Hypersensitivity to fluocinonide or any component of the formulation; viral, fungal, or tubercular skin lesions, herpes simplex.

Warnings and precautions

Systemic absorption of topical corticosteroids may cause hypothalamic-pituitary-adrenal (HPA) axis suppression (reversible), particularly in younger children. HPA axis suppression may lead to adrenal crisis. Risk is increased when used over large surface areas, for prolonged periods, or with occlusive dressings. Allergic contact dermatitis can occur, this is usually diagnosed by failure to heal rather than clinical exacerbation. Prolonged treatment with corticosteroids has been associated with the development of Kaposi’s sarcoma (case reports); if noted, discontinuation of therapy should be considered. Lower-strength cream (0.05%) may be used cautiously on face or opposing skin surfaces that may rub or touch (e.g. skin folds of the groin, axilla, and breasts); higher-strength (0.1%) should not be used on the face, groin, or axillae. Use of the 0.1% cream for >2 weeks is not recommended.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart